What question did this study set out to answer?

To examine the effects of CXCL12 inhibition on the tumor microenvironment and immunotherapy efficacy in GBM.

May 7, 2026Neuro-Oncology Advances0 citationsOpen Access

Inhibition of chemokine CXCL12 modulates the tumor microenvironment in GBM and potentiates ICI efficacy in a Tissue-Specific manner

CMChen Makranz CHCaitlin Huguely MZM ZHANG

Key Points

To examine the effects of CXCL12 inhibition on the tumor microenvironment and immunotherapy efficacy in GBM.
Utilized a syngeneic murine SB28 GBM model resistant to immune checkpoint inhibitors (ICI).
Administered vehicle, ICI, CXCL12 inhibitor (NOX-A12), or a combination of NOX-A12 with ICI.
Assessed immune cell populations, tumor growth, and mouse survival after treatments.
ICI alone increased effector CD8+ T cells in subcutaneous tumors but not in orthotopic tumors.
Combination of NOX-A12 and ICI increased effector CD8+ and CD4+ T cells in both tumor models.
Combination therapy reduced MHC-IIlow tumor-associated macrophages in subcutaneous tumors and slowed tumor growth.
No survival benefit in orthotopic tumors despite T cell modulation, indicating the role of tumor-associated macrophages in GBM resistance.

Abstract

Abstract Background Immunotherapy, while effective for many extra-cranial solid tumors, has not shown benefits against GBM. Limited T cell infiltration and an immunosuppressive tumor microenvironment (TME) are among the main barriers to successful immunotherapy. We hypothesized that blocking the chemokine CXCL12 would modulate the TME composition and reverse GBM resistance to immunotherapy. Methods We used a syngeneic murine SB28 GBM model resistant to immune checkpoint inhibitor (ICI) and compared orthotopic and subcutaneous tumors to differentiate tumor-intrinsic factors from CNS-related barriers. We treated SB28 tumor-bearing mice with vehicle, ICI, CXCL12 inhibitor (NOX-A12), or a combination of NOX-A12 with ICI. We assessed treatment effects on immune cell populations in the blood and the TME, and on tumor growth and mouse survival. Results ICI alone increased effector CD8+T cells in subcutaneous tumors but did not alter immune subsets in intracranial tumors. The combination of NOX-A12 and ICI increased effector CD8+ and CD4+ T cells in both models. In subcutaneous tumors, combination treatment also reduced MHC-IIlow tumor-associated macrophages (TAM) and slowed tumor growth. However, in orthotopic tumors, TAM populations remained unaffected, and survival was not extended, despite similar T cell modulation, supporting the role of TAM in mediating GBM resistance to ICI. Conclusion CXCL12 inhibition demonstrates therapeutic potential in facilitating anti-tumor immune response by dual mechanism, including T cell expansion and TAM reduction. The inability to deplete TAMs and improve survival in intracranial GBM underscores the need to address brain-specific mechanisms underlying TAM persistence to advance immunotherapy in GBM.

Perguntar à IA

Bookmark

View Full Paper